Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Odkrivanje raka materničnega vratu s testiranjem za visokorizične humane viruse papiloma
Authors:ID Uršič-Vrščaj, Marjetka (Author)
Files:.pdf PDF - Presentation file, download (110,86 KB)
MD5: 4373774E9B55D2141ED5B78E0FE96282
PID: 20.500.12556/dirros/b28b6054-f369-46f5-bb6b-490ee79c1343
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Publication status:Published
Publication version:Version of Record
Year of publishing:2009
Number of pages:str. 7-10
Numbering:Letn. 13, št. 1
PID:20.500.12556/DiRROS-8815 New window
UDC:616-006
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-O9A4ZXJT
COBISS.SI-ID:25688793 New window
Copyright:by Authors
Note:BSDOCID145197;
Publication date in DiRROS:31.08.2018
Views:3530
Downloads:856
Metadata:XML DC-XML DC-RDF
:
URŠIČ-VRŠČAJ, Marjetka, 2009, Odkrivanje raka materničnega vratu s testiranjem za visokorizične humane viruse papiloma. Onkologija [online]. 2009. Vol. 13, no. 1, p. 7–10. [Accessed 24 March 2025]. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=8815
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Cervical Cancer Detection Using High-Risk Human Papillomavirus Testing
Abstract:Since the development of cytology-based cervical cancer screening using PAP test in the mid-20th century, the PAP test has been accepted as a method for secondary prevention of cervical cancer. Screening for cervical cancer precursors by cytology has been very successful in the countries with high-quality programs and good coverage of the population at risk. Low-grade abnormalities are the most common type of cytologic abnormalities. In several countries, it is currently recommended to follow up these women by performing PAP smear tests in 6-month intervals. If the low-grade abnormalities do not normalize, colposcopy should be done, which every now and then leads to several unnecessary referrals, associated anxiety and costs. Human papillomavirus (HPV) infection is very common in young women after the onset of sexual activity and, when it persists, it may result in cervical intraepithelial neoplasia (CIN). The recognition of the strong causal relationship between the persistent infection of the genital tract with high-risk HPV types and the occurrence of cervical cancer has resulted in the development of a number of HPV DNA and HPV RNA detection systems. The detection of high-risk HPV DNA is considered to be potentially useful in three applications: (1) as a triage test to select the women with minor cytologic lesions in their PAP smears who need a referral for colposcopic diagnosis and treatment, (2) as a follow-up test for the treated high-grade intraepithelial lesion, and (3.) as a primary screening test alone or in combination with PAP test to detect cervical cancer precursors. There are clear benefits of the use of HPV DNA testing in the triage of atypical squamous cells, mild dyscaryotic cells in older women, and in the post-treatment surveillance of women after treatment for CIN. There is an increasing need for more information and educational programs about HPV.


Archive

niGradiv

Back